All posts

Tantalus Systems is a Buy, says Paradigm

After preliminary fourth quarter numbers from smart power grid company Tantalus Systems (Tantalus Systems Stock Quote, Charts, News, Analysts, Financials TSX:GRID), Paradigm Capital analyst Daniel Rosenberg is staying bullish on the stock. Rosenberg delivered a note to clients on Thursday, saying GRID shares are looking attractive at current levels.

Burnaby, BC-based Tantalus, which develops mission-critical smart grid solutions for public power and electric utilities, announced on Thursday preliminary fourth quarter revenue of $12.0-$12.2 million and adjusted EBITDA at $75,000-$150,000. The topline would represent a 60 per cent improvement over the Q4 2021, while total revenue for 2022 at $39.5-$39.7 million would represent a 23 per cent year-over-year growth rate. (All figures in US dollars except where noted otherwise.)

“As we turn our sights towards 2023, we continue to witness improving visibility into our financial position, strong demand for our new TRUSense Gateway product offering and favourable tailwinds across the utility industry,” said Pete Londa, President & CEO, in a press release.

Rosenberg said the consensus Q4 revenue call had been $11.0 million, while his was $11.2 million, commenting that Tantalus’ fourth quarter saw a boost from backlog throughput following on the easing of supply chain disruptions, along with Tantalus’ M&A from earlier in 2022. On EBITDA, the Street had forecasted a loss of $100,000, while Rosenberg was at breakeven.

Rosenberg related that with $5.9 million in cash as of the end of the 2022 year, the company expects to have sufficient funds to support ongoing operations and R&D. 

“We view the news as a slight positive, as it suggests that Tantalus will continue to improve its margin profile despite an inflationary environment,” Rosenberg wrote.

Since debuting on the TSX in early 2021, Tantalus’ share price has dropped over two-thirds of its value, although shares are up in recent weeks. 

With the update, Rosenberg maintained a “Buy” rating on GRID and C$3.25 target price, which at press time represented a projected one-year return of 210 per cent. The analyst has based his target on a 2.8x multiple of his 2023 EV/Revenue estimate, with the stock currently trading at 1.0x 2023 EV/Revenue compared to its peer group at 3.7x, according to Rosenberg.

“Following a broader stock market sell-off in 2022, we believe shares screen attractively. Shares have retraced 43 per cent over a 12-month period compared to our peer group average of eight per cent. We believe shares could re-rate higher later this year as the company turns cash flow positive (we expect this to be a mid-year event),” he said.

Tagged with: grid
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

RBC: These are the tariffs that are hurting Canada

RBC economist Salim Zanzana said targeted U.S. tariffs on steel, aluminum and auto products are disproportionately impacting Canadian manufacturers, with… [Read More]

6 hours ago

Should you sell your BlackBerry stock?

Ahead of its Q2 report, RBC analyst Paul Treiber remains on the fence about BlackBerry (BlackBerry Stock Quote, Chart, News,… [Read More]

15 hours ago

Should you sell your Cingulate stock?

In a Sept. 18 report, Roth Capital Markets analyst Boobalan Pachaiyappan reiterated a “Buy” rating and US$10.00 target on Cingulate… [Read More]

4 days ago

This Canadian smallcap stock has big potential, analyst says

In a Sept. 17 report, Haywood Capital Markets analyst Gianluca Tucci said a new memorandum of understanding signed by MineHub… [Read More]

4 days ago

Quebecor wins price target raise at National Bank

National Bank Financial analyst Adam Shine raised his price target on Quebecor (Quebecor Stock Quote, Chart, News, Analysts, Financials TSE:QBR.B)… [Read More]

5 days ago

Cipher Pharmaceuticals is about to ramp up, Stifel says

In a Sept. 16 note, Stifel analyst Justin Keywood reiterated a “Buy” rating and C$20.00 target on Cipher Pharmaceuticals (Cipher… [Read More]

5 days ago